JP2025508406A - Cns関連障害を処置するための神経活性ステロイド - Google Patents

Cns関連障害を処置するための神経活性ステロイド Download PDF

Info

Publication number
JP2025508406A
JP2025508406A JP2024548386A JP2024548386A JP2025508406A JP 2025508406 A JP2025508406 A JP 2025508406A JP 2024548386 A JP2024548386 A JP 2024548386A JP 2024548386 A JP2024548386 A JP 2024548386A JP 2025508406 A JP2025508406 A JP 2025508406A
Authority
JP
Japan
Prior art keywords
treatment
compound
subject
antidepressant
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024548386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508406A5 (cg-RX-API-DMAC7.html
Inventor
ロバート アルフォンソ ラサー,
ジェイムズ ドハーティ,
ジェフリー マーティン ジョナス,
スティーブン ジェイ ケインズ,
ハンダン グンドゥーズ-ブルース,
エイミー イー. ブロック,
ティモシー ワイ. マリアーノ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics LLC
Original Assignee
Sage Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics LLC filed Critical Sage Therapeutics LLC
Publication of JP2025508406A publication Critical patent/JP2025508406A/ja
Publication of JP2025508406A5 publication Critical patent/JP2025508406A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024548386A 2022-02-16 2023-02-15 Cns関連障害を処置するための神経活性ステロイド Pending JP2025508406A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263310581P 2022-02-16 2022-02-16
US63/310,581 2022-02-16
US202263337828P 2022-05-03 2022-05-03
US63/337,828 2022-05-03
US202363482200P 2023-01-30 2023-01-30
US63/482,200 2023-01-30
PCT/US2023/013098 WO2023158668A1 (en) 2022-02-16 2023-02-15 Neuroactive steroids for treatment of cns-related disorders

Publications (2)

Publication Number Publication Date
JP2025508406A true JP2025508406A (ja) 2025-03-26
JP2025508406A5 JP2025508406A5 (cg-RX-API-DMAC7.html) 2026-02-25

Family

ID=85569830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024548386A Pending JP2025508406A (ja) 2022-02-16 2023-02-15 Cns関連障害を処置するための神経活性ステロイド

Country Status (11)

Country Link
US (1) US20250295674A1 (cg-RX-API-DMAC7.html)
EP (1) EP4479032A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508406A (cg-RX-API-DMAC7.html)
KR (1) KR20240148425A (cg-RX-API-DMAC7.html)
CN (1) CN119072304A (cg-RX-API-DMAC7.html)
AU (1) AU2023220976A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252357A1 (cg-RX-API-DMAC7.html)
IL (1) IL315023A (cg-RX-API-DMAC7.html)
MX (1) MX2024009974A (cg-RX-API-DMAC7.html)
TW (1) TW202341995A (cg-RX-API-DMAC7.html)
WO (1) WO2023158668A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MX2023012727A (es) * 2021-04-29 2023-11-08 Sage Therapeutics Inc Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto.
CN117442618B (zh) * 2023-10-23 2025-11-14 国科大杭州高等研究院 化合物ly2940094在制备治疗中枢神经系统脱髓鞘疾病药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
CN111454318A (zh) * 2019-01-20 2020-07-28 浙江易众化工有限公司 抗抑郁药物sage-217的晶型及其制备方法
CA3187178A1 (en) 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof

Also Published As

Publication number Publication date
AU2023220976A1 (en) 2024-09-05
WO2023158668A1 (en) 2023-08-24
EP4479032A1 (en) 2024-12-25
US20250295674A1 (en) 2025-09-25
TW202341995A (zh) 2023-11-01
MX2024009974A (es) 2024-09-30
CA3252357A1 (en) 2023-08-24
IL315023A (en) 2024-10-01
KR20240148425A (ko) 2024-10-11
CN119072304A (zh) 2024-12-03

Similar Documents

Publication Publication Date Title
US20250295674A1 (en) Neuroactive steroids for treatment of cns-related disorders
US20220152057A1 (en) Methods and compositions for treating various disorders
US20220323462A1 (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20240216395A1 (en) 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
US20230018765A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
JP2025510913A (ja) 双極性障害の処置のための5-MeO-DMT
TWI826380B (zh) Nk-1 拮抗劑組合物及用於治療抑鬱症之方法
WO2025122747A1 (en) Treatment of moderate-to-severe asthma by administering rilzabrutinib
JP2025537277A (ja) 患者にエコピパム療法を提供する方法
WO2023159035A1 (en) Neuroactive steroids for treatment of cns-related disorders
CN117580581A (zh) 用于治疗重度抑郁障碍和产后抑郁症的19-去甲c3,3-二取代的c21-n-吡唑基类固醇
HK40090080B (en) Cyclobenzaprine treatment for sexual dysfunction
HK40090080A (zh) 性功能障碍的环苯扎林治疗
HK40081935A (en) Treatment of amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260216